Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Researchers in the US have mapped a SARS-CoV-2 protein, which could help use drugs developed to treat SARS coronavirus as effective treatments for the new Covid-19 disease.

A team of researchers from the University of Chicago, the US Department of Energy’s (DOE) Argonne National Laboratory, Northwestern University Feinberg School of Medicine and the University of California, Riverside School of Medicine (UCR) carried out the mapping.

According to the team, the Nsp15 protein from SARS-CoV-2 is 89% similar to the SARS-CoV protein.

Previous SARS studies published in 2010 show that Nsp15 inhibition can slow viral replication, offering hope for the use of Nsp15-targeting drugs to treat Covid-19.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Mapping of a 3D protein structure allows better insights into the virus’ replication in human cells.

Northwestern University microbiology-immunology professor Karla Satchell said: “The NSP15 protein has been investigated in SARS as a novel target for new drug development, but that never went very far because the SARS epidemic went away, and all new drug development ended.

“Some inhibitors were identified but never developed into drugs. The inhibitors that were developed for SARS now could be tested against this protein.”

The team plans to release the Nsp15 protein structure to the scientific community on March 4 on the RSCB Protein Data Bank.

Last month, researchers from the University of Texas at Austin and the National Institutes of Health (NIH) in the US created a 3D map of the coronavirus to help design vaccines and antiviral treatments.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact